MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1200/jco-25-00582

Медицинская библиотека · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025

Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi Trial.

Ratan Ravin, Kasper Bernd, Alcindor Thierry, Schöffski Patrick, van der Graaf Winette T A, Federman Noah, Bui Nam Q, D'Amato Gina, Riedel Richard F, Attia Steven, Chawla Sant, Lim Allison, Tumminello Brad, Oton Ana B, Chu Yucheng, Zhou Shengfan, Gounder Mrinal

СтатьяКлиническое исследование III фазыРандомизированное исследованиеМногоцентровое исследованиеПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

In the phase III placebo-controlled DeFi trial (ClinicalTrials.gov identifier: NCT03785964) primary analysis, nirogacestat showed significant improvement versus placebo in progression-free survival (PFS), objective response rate (ORR), and patient-reported outcomes (PRO) in adult patients with progressing desmoid tumors (DT; median [range] exposure: 20.6 [0.3-33.6] months). Here, long-term nirogacestat efficacy and safety were evaluated in patients randomly assigned to nirogacestat and followed through the final data cutoff date of December 19, 2024. End points included PFS and ORR per RECIST v1.1, PRO, and safety. The median (range) duration of exposure was 33.6 (0.3-61.8) months. Median PFS was not reached. The ORR with up to 4 years of nirogacestat treatment was 45.7% (32 of 70), with three additional partial and three additional complete responses since the primary analysis. Further target tumor size reduction occurred in most patients. Benefits in PROs were sustained while on treatment. Frequently reported treatment-emergent adverse events (TEAEs) decreased in incidence and severity over time. Since the primary analysis, four patients discontinued nirogacestat because of TEAEs between years 2 and 4. In conclusion, long-term continuous nirogacestat treatment was associated with further tumor size reductions, durable objective responses, sustained PRO benefits, and a manageable safety profile consistent with the primary analysis.

Для цитирования: Ratan Ravin, Kasper Bernd, Alcindor Thierry, Schöffski Patrick, van der Graaf Winette T A, Federman Noah, Bui Nam Q, D'Amato Gina, Riedel Richard F, Attia Steven, Chawla Sant, Lim Allison, Tumminello Brad, Oton Ana B, Chu Yucheng, Zhou Shengfan, Gounder Mrinal. Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi Trial.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025. DOI: 10.1200/jco-25-00582.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.